STOCK TITAN

Sabby group reports 9.9% Tempest Therapeutics (TPST) ownership block

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Sabby Volatility Warrant Master Fund, Sabby Management, and Hal Mintz report a sizable position in Tempest Therapeutics. They collectively report beneficial ownership of 492,223 shares of Tempest Therapeutics common stock, representing 9.9% of the outstanding class as of the event date. All three reporting persons state they have shared power to vote and dispose of these shares and no sole voting or dispositive power. They also certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Tempest Therapeutics, indicating a passive investment intent.

Positive

  • None.

Negative

  • None.

Insights

Sabby entities disclose a passive 9.9% stake in Tempest Therapeutics.

Sabby Volatility Warrant Master Fund, Sabby Management, and Hal Mintz report beneficial ownership of 492,223 Tempest Therapeutics common shares, or 9.9% of the class. Voting and dispositive authority over these shares is reported as shared, with no sole power listed for any of the filers.

The Schedule 13G certification states that the position was not acquired and is not held to change or influence control of Tempest Therapeutics, which aligns with a passive-investor filing status. This distinguishes the filing from a control-seeking position that would typically be reported on a different schedule.

While a 9.9% stake is a meaningful ownership block, the filing emphasizes passive intent. Future position changes, if any, would generally be reflected in subsequent ownership reports rather than being implied here.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



SABBY MANAGEMENT, LLC
Signature:/s/ Robert Grundstein
Name/Title:COO
Date:01/21/2026
Hal Mintz
Signature:/S/ HAL MINTZ
Name/Title:HAL MINTZ
Date:01/14/2026
Sabby Volatility Warrant Master Fund, Ltd.
Signature:/s/ Harry Thompson
Name/Title:Harry Thompson
Date:01/21/2026

FAQ

What ownership stake in TPST is reported in this Schedule 13G?

The filers report beneficial ownership of 492,223 shares of Tempest Therapeutics common stock, representing 9.9% of the outstanding class.

Who are the reporting persons in the Tempest Therapeutics (TPST) Schedule 13G?

The reporting persons are Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz.

Do the Sabby entities and Hal Mintz have control intent over Tempest Therapeutics (TPST)?

The filers certify the securities were not acquired and are not held to change or influence control of Tempest Therapeutics, indicating passive investment intent.

How much voting and dispositive power do the Sabby filers report over TPST shares?

Each reporting person lists 0 shares with sole voting or dispositive power and 492,223 shares with shared voting and dispositive power.

What class of Tempest Therapeutics (TPST) securities is covered by this Schedule 13G?

The filing covers common stock of Tempest Therapeutics, Inc., identified by CUSIP 87978U207.

What is the event date referenced in the Tempest Therapeutics (TPST) Schedule 13G?

The date of the event requiring the filing is listed as 12/31/2025.
Tempest Therapeutics Inc

NASDAQ:TPST

TPST Rankings

TPST Latest News

TPST Latest SEC Filings

TPST Stock Data

12.71M
4.92M
0.11%
18.87%
4.1%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRISBANE